DNA vaccines against leptospirosis: A literature review
- PMID: 28882437
- DOI: 10.1016/j.vaccine.2017.08.067
DNA vaccines against leptospirosis: A literature review
Abstract
Leptospirosis is an infectious disease caused by pathogenic Leptospira species. The vaccines that are currently available for leptospirosis are composed of whole-cell preparations and suffer from limitations such as low efficacy, multiple side-effects, poor immunological memory and lack of cross-protection against different serovars of Leptospira spp. In light of the global prevalence of this disease, the development of a more effective vaccine against leptospirosis is of paramount importance. Genetic immunization is a promising alternative to conventional vaccine development. In the last 25years, several novel strategies have been developed for increasing the efficacy of DNA vaccines. Examples of such strategies include the introduction of novel plasmid vectors, adjuvants, alternate delivery routes, and prime-boost regimens. Herein we discuss the latest and most promising advances that have been made in developing DNA vaccines against leptospirosis. We also deliberate over the future directions that must be undertaken in order to improve results in this field.
Keywords: Antigens; DNA vaccine; Leptospirosis.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis.Mem Inst Oswaldo Cruz. 2015 Dec;110(8):989-95. doi: 10.1590/0074-02760150222. Epub 2015 Dec 11. Mem Inst Oswaldo Cruz. 2015. PMID: 26676320 Free PMC article.
-
Antigenic potential of a recombinant polyvalent DNA vaccine against pathogenic leptospiral infection.Microb Pathog. 2018 Nov;124:136-144. doi: 10.1016/j.micpath.2018.08.028. Epub 2018 Aug 21. Microb Pathog. 2018. PMID: 30138761
-
Immunogenicity of a DNA and Recombinant Protein Vaccine Combining LipL32 and Loa22 for Leptospirosis Using Chitosan as a Delivery System.J Microbiol Biotechnol. 2015 Apr;25(4):526-36. doi: 10.4014/jmb.1408.08007. J Microbiol Biotechnol. 2015. PMID: 25348693
-
Advances & challenges in leptospiral vaccine development.Indian J Med Res. 2018 Jan;147(1):15-22. doi: 10.4103/ijmr.IJMR_1022_16. Indian J Med Res. 2018. PMID: 29749356 Free PMC article. Review.
-
Revisiting the Development of Vaccines Against Pathogenic Leptospira: Innovative Approaches, Present Challenges, and Future Perspectives.Front Immunol. 2022 Jan 3;12:760291. doi: 10.3389/fimmu.2021.760291. eCollection 2021. Front Immunol. 2022. PMID: 35046936 Free PMC article. Review.
Cited by
-
Innovation-driven trend shaping COVID-19 vaccine development in China.Front Med. 2023 Dec;17(6):1096-1116. doi: 10.1007/s11684-023-1034-6. Epub 2023 Dec 16. Front Med. 2023. PMID: 38102402 Review.
-
A global overview of the most important zoonotic bacteria pathogens transmitted from Rattus norvegicus to humans in urban environments.Infect Med (Beijing). 2022 Jul 30;1(3):192-207. doi: 10.1016/j.imj.2022.07.002. eCollection 2022 Sep. Infect Med (Beijing). 2022. PMID: 38077628 Free PMC article. Review.
-
Improvement the expression and purification of Loa22: a lipoprotein with OmpA domain from pathogenic Leptospira serovars.Iran J Microbiol. 2023 Oct;15(5):674-684. doi: 10.18502/ijm.v15i5.13873. Iran J Microbiol. 2023. PMID: 37941886 Free PMC article.
-
Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19).Arch Microbiol. 2023 Mar 30;205(4):150. doi: 10.1007/s00203-023-03480-5. Arch Microbiol. 2023. PMID: 36995507 Free PMC article. Review.
-
Challenges for the development of a universal vaccine against leptospirosis revealed by the evaluation of 22 vaccine candidates.Front Cell Infect Microbiol. 2022 Oct 7;12:940966. doi: 10.3389/fcimb.2022.940966. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36275031 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
